Roivant ranks 28th in the 2025 Fortune Best Workplaces in BioPharma list, reflecting its strong workplace culture.
Quiver AI Summary
Roivant has been recognized for the first time in the 2025 Fortune Best Workplaces in BioPharma™ List, ranking 28th in the small and medium category. This distinction, awarded by Great Place To Work® and Fortune magazine, highlights Roivant as one of the best employers in the biotechnology and pharmaceutical sector, based on survey responses from nearly 40,000 employees at certified companies. CEO Matt Gline expressed pride in this achievement, noting it reflects the company's focus on creating an empowering and talent-oriented culture. The competitive selection process involved analyzing over 1.3 million employee surveys to ensure a fair assessment across diverse demographics. Roivant is a biopharmaceutical company committed to enhancing patient lives through the development of important medicines and incubating innovative health technology startups.
Potential Positives
- Roivant has been recognized for the first time on the 2025 Fortune Best Workplaces in BioPharma™ List, ranking 28th in the small & medium category.
- This recognition underscores Roivant's commitment to fostering a positive workplace culture, as highlighted by its CEO's statement emphasizing the importance of its team.
- The award is based on employee feedback from a significant survey that analyzed close to 40,000 responses from companies in the biotechnology and pharmaceutical industry, adding credibility to the recognition.
- Being named among the best workplaces can enhance Roivant's attractiveness to potential talent, supporting its goal of accelerating medicine development and commercialization.
Potential Negatives
- Despite being recognized on the Fortune Best Workplaces in BioPharma List, Roivant's ranking of 28th out of many competitors may indicate that while they have a positive workplace culture, they still have significant room for improvement compared to others in the industry.
- The press release does not provide any specific details about employee satisfaction metrics or areas that Roivant is addressing to enhance workplace culture, which could raise questions about the depth of the company's commitment to its employees.
- Being a first-time entrant on the list may suggest that Roivant has not historically prioritized workplace culture to the same degree as its competitors, prompting potential concerns about employee engagement in the past.
FAQ
What is the significance of Roivant being named to the 2025 Fortune Best Workplaces in BioPharma List?
Being named to this list signifies Roivant's recognition as one of the best companies to work for in the biotechnology sector.
How did Roivant rank in the Fortune Best Workplaces in BioPharma List?
Roivant ranked 28th in the small and medium category of the 2025 Fortune Best Workplaces in BioPharma List.
What factors contributed to Roivant's selection for the award?
The award is based on survey responses from nearly 40,000 employees at certified companies, reflecting workplace culture and employee experiences.
Who is the CEO of Roivant and what did he say about this recognition?
Matt Gline is the CEO of Roivant, who expressed pride in the team's commitment to a talent-oriented culture following the award recognition.
How is the Best Workplaces in BioPharma List determined?
The list is determined by analyzing over 1.3 million confidential employee surveys focusing on various workplace experience factors.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ROIV Congressional Stock Trading
Members of Congress have traded $ROIV stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ROIV stock by members of Congress over the last 6 months:
- REPRESENTATIVE LISA C. MCCLAIN purchased up to $15,000 on 06/17.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$ROIV Insider Trading Activity
$ROIV insiders have traded $ROIV stock on the open market 18 times in the past 6 months. Of those trades, 0 have been purchases and 18 have been sales.
Here’s a breakdown of recent trading of $ROIV stock by insiders over the last 6 months:
- VIVEK RAMASWAMY has made 0 purchases and 9 sales selling 4,565,211 shares for an estimated $54,125,623.
- ERIC VENKER (President & Immunovant CEO) has made 0 purchases and 9 sales selling 2,250,000 shares for an estimated $24,931,666.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ROIV Hedge Fund Activity
We have seen 175 institutional investors add shares of $ROIV stock to their portfolio, and 186 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- QVT FINANCIAL LP removed 36,412,144 shares (-55.3%) from their portfolio in Q2 2025, for an estimated $410,364,862
- VIKING GLOBAL INVESTORS LP removed 11,775,973 shares (-25.6%) from their portfolio in Q2 2025, for an estimated $132,715,215
- MORGAN STANLEY added 8,767,207 shares (+24.4%) to their portfolio in Q2 2025, for an estimated $98,806,422
- INVESCO LTD. removed 8,196,427 shares (-83.0%) from their portfolio in Q2 2025, for an estimated $92,373,732
- DIMENSIONAL FUND ADVISORS LP added 5,297,818 shares (+204.7%) to their portfolio in Q2 2025, for an estimated $59,706,408
- TOMS CAPITAL INVESTMENT MANAGEMENT LP removed 4,095,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $46,150,650
- FMR LLC added 3,842,770 shares (+7.4%) to their portfolio in Q2 2025, for an estimated $43,308,017
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ROIV Analyst Ratings
Wall Street analysts have issued reports on $ROIV in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Citigroup issued a "Buy" rating on 09/02/2025
- HC Wainwright & Co. issued a "Buy" rating on 06/18/2025
To track analyst ratings and price targets for $ROIV, check out Quiver Quantitative's $ROIV forecast page.
$ROIV Price Targets
Multiple analysts have issued price targets for $ROIV recently. We have seen 2 analysts offer price targets for $ROIV in the last 6 months, with a median target of $17.0.
Here are some recent targets:
- Samantha Semenkow from Citigroup set a target price of $16.0 on 09/02/2025
- Douglas Tsao from HC Wainwright & Co. set a target price of $18.0 on 06/18/2025
Full Release
BASEL, Switzerland and LONDON and NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Great Place To Work ® and Fortune magazine have selected Roivant (Nasdaq: ROIV) for the 2025 Fortune Best Workplaces in BioPharma™ List . This is Roivant’s first time being named to this prestigious list, coming in at 28th place in the small & medium category. Earning a spot means that Roivant is one of the best companies to work for in the country.
The Best Workplaces in BioPharma award is based on analysis of survey responses from nearly 40,000 employees at Great Place To Work Certified™ companies in the biotechnology and pharmaceutical industry.
“We are incredibly honored to be named one of the Best Workplaces in BioPharma by Fortune and Great Place To Work,” said Matt Gline, CEO of Roivant. “This recognition reflects our team's commitment to creating an empowering, high-performance, and talent-oriented culture. It's our people who make Roivant a great place to work, and we are proud to celebrate this achievement together.”
The Best Workplaces in BioPharma list is highly competitive. Great Place To Work, the global authority on workplace culture, determines its lists using its proprietary Trust Index™ Survey to evaluate and certify thousands of organizations in America’s largest ongoing annual workforce study, based on over 1.3 million survey responses and data from companies representing more than 8.4 million employees.
Survey responses reflect a comprehensive picture of the workplace experience. Honorees were selected based on their ability to offer positive outcomes for employees regardless of job role, race, gender, sexual orientation, work status, or other demographic identifier.
About the Fortune Best Workplaces in BioPharma List
Great Place To Work selected the 2025 Fortune Best Workplaces in BioPharma by analyzing over 1.3 million confidential employee surveys, representing the experiences of 8.4 million workers in the U.S. in 2024 and 2025. Of those responses, nearly 40,000 came from employees at Great Place To Work Certified companies in the biotechnology and pharmaceutical industry, and this list is based on that feedback. Company rankings are derived from 60 employee experience questions within the Great Place To Work Trust Index™ Survey . Companies with 10 to 999 employees competed in the small and medium category. Companies with 1,000 or more employees were considered for the large category. Read the full methodology.
To get on this list next year, start here.
About Great Place To Work
As the global authority on workplace culture, Great Place To Work brings 30 years of groundbreaking research and data to help every place become a great place to work for all. Its proprietary platform and Great Place To Work Model help companies evaluate the experience of every employee, with exemplary workplaces becoming Great Place To Work Certified and receiving recognition on a coveted Best Workplaces™ List.
Follow Great Place To Work on LinkedIn , X , and Instagram or visit greatplacetowork.com and sign up for the newsletter to learn more.
About Fortune
Fortune upholds a legacy of award-winning writing and trusted reporting for executives who want to make business better. Independently owned, with a global perspective and digital agility, Fortune tells the stories of a new generation of innovators, builders, and risk takers. Online and in print, Fortune measures corporate performance through rigorous benchmarks and holds companies accountable. Fortune creates communities by convening true thought leaders and iconoclasts — those who shape industry, commerce, and society — through powerful and prestigious lists, events, and conferences, such as the iconic Fortune 500, the CEO Initiative , and Most Powerful Women. For more information, visit fortune.com .
About Roivant
Roivant (Nasdaq: ROIV) is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. Beyond therapeutics, Roivant also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. For more information, visit https://roivant.com .
